New drugs for C. difficile cost almost five times more
February 1, 2012 - I was asked to be interviewed by a representative of Edelman, a firm that is handling public relations for DIFICID, a new drug that treats C. difficile infections. They sent me a questionnaire to find out more about who we are, what our perspective is on this drug, and whether we would like to partner with a drug company on advocacy issues. I agreed to the interview to see what it would be like. In the mean time, I did a bit of research on the drug.